DAN-405

DAN-405 is a preclinical antibody-drug conjugate being developed by Dantari as a targeted high-capacity drug conjugate against prostate-specific membrane antigen (PSMA) for the treatment of castration-resistant prostate cancer. It uses a PSMA-targeting antibody linked to a highly loaded tubulin-inhibiting cytotoxic payload, with a drug–antibody ratio of approximately 60 enabled by Dantari’s Targeted High-capacity Drug Conjugate (T-HDC) platform.[1][3][7] By binding PSMA on prostate cancer cells and delivering a large quantity of tubulin inhibitor intracellularly, DAN-405 is intended to induce mitotic arrest and apoptosis while limiting systemic exposure, but it has not yet entered clinical trials and remains in preclinical development.[1][3][7]